Table SI. Inclusion and exclusion criteria

**Inclusion criteria**
- Chronic plaque psoriasis
- Prospective or retrospective
- Thirty participants or more
- Daily practice, database, registries, “real-world”, “real-life”, observational, cohort
- Patients aged ≥ 18 years
- English, Dutch or German language
- Article reports on one of the following effectiveness outcomes: PASI, PhGA on a scale of 0–5, 0–6 or 0–7 or BSA
- Reporting on the effectiveness of following treatments: adalimumab, etanercept, infliximab, ustekinumab, acitretin, fumarates, cyclosporine, or methotrexate
- Reporting data analysed with the as-treated approach (per protocol analysis)

**Exclusion criteria**
- Case reports
- RCTs or clinical trials
- Safety studies
- *In vitro* studies and other laboratory studies
- Pharmacokinetic studies
- Cost-effectiveness studies
- Open-label studies with a stringent protocol not reflecting daily practice
- Studies not reporting the time point at which effectiveness was measured
- Studies not reporting the dosage of treatment
- Studies not reporting data separately per treatment
- Studies reporting solely on non-systemic treatments such as phototherapy and topical therapies
- Studies reporting solely on alefacept or efalizumab since these agents are no longer available for psoriasis treatment
- Articles reporting on a combination of plaque psoriasis with other subtypes of psoriasis when the effectiveness data solely on chronic plaque psoriasis could not be extracted from the article
- Studies describing only outcomes on psoriatic arthritis
- Studies on specific psoriasis patient populations (e.g. psoriasis patients with HIV or hepatitis)
- Studies in which conventional systemic agents were combined with other conventional systemic therapies
- In patient cohorts treated with biologics, combination with conventional systemic was not excluded but described when appropriate

RCT: randomized controlled trial; PASI: Psoriasis Area and Severity Index; PhGA: Physician’s Global Assessment; BSA: body surface area.